Sabby Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Sabby Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-3,900	Closed	-$124K	–	379
2015 Q4	$201K	Sell	3,900 -7,301	-65%	-$354K	0.01%	282
2015 Q3	$477K	Buy	+11,201	New	+$540K	0.02%	296

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Sabby Management's PTLA Position: Q1 2016 in Review

Sabby Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2016, closing a stake of 3,900 shares — an estimated $124K sold.

Sabby Management first reported a position in PTLA in Q3 2015 and held it in 2 quarters. The position peaked at $477K in Q3 2015. 167 funds tracked by Wall St. Rank hold PTLA as of Q1 2016.

Sabby Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
Sabby Management sold 3,900 Portola Pharmaceuticals, Inc. shares in Q1 2016, an estimated $124K.
Sabby Management first reported a position in Portola Pharmaceuticals, Inc. in Q3 2015 and held it in 2 quarters.
Sabby Management's Portola Pharmaceuticals, Inc. position peaked at $477K in Q3 2015.
167 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2016.

Based on Sabby Management's 13F filing for Q1 2016, filed 13 May 2016.